title: PD-1, CTLA-4 Point to Drug Response.
abstract: In a study of patients with metastatic melanoma, researchers reported that higher numbers of cytotoxic T cells positive for both PD-1 and CTLA-4 in the tumor predicted response to anti-PD-1 therapy and improved progression-free survival.
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000235:genetics*; D019070:Cell Lineage / Q000187:drug effects; D018572:Disease-Free Survival; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab